GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (OTCPK:APTCF) » Definitions » Cash Ratio

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Cash Ratio : 0.46 (As of Apr. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Proteome Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Advanced Proteome Therapeutics's Cash Ratio for the quarter that ended in Apr. 2023 was 0.46.

Advanced Proteome Therapeutics has a Cash Ratio of 0.46. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Advanced Proteome Therapeutics's Cash Ratio or its related term are showing as below:

APTCF's Cash Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.11
* Ranked among companies with meaningful Cash Ratio only.

Advanced Proteome Therapeutics Cash Ratio Historical Data

The historical data trend for Advanced Proteome Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Cash Ratio Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.16 - 0.82 0.44

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.44 0.30 0.24 0.46

Competitive Comparison of Advanced Proteome Therapeutics's Cash Ratio

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Cash Ratio falls into.



Advanced Proteome Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Advanced Proteome Therapeutics's Cash Ratio for the fiscal year that ended in Jul. 2022 is calculated as:

Cash Ratio (A: Jul. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.544/1.245
=0.44

Advanced Proteome Therapeutics's Cash Ratio for the quarter that ended in Apr. 2023 is calculated as:

Cash Ratio (Q: Apr. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.039/0.084
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Proteome Therapeutics  (OTCPK:APTCF) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Advanced Proteome Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Headlines